Fresenius SE & Co KGaA (FRA:FRE) has been given a €50.00 ($58.14) price target by equities research analysts at Morgan Stanley in a report issued on Wednesday, Borsen Zeitung reports. The firm presently has a “neutral” rating on the stock. Morgan Stanley’s price target indicates a potential upside of 5.78% from the company’s previous close.
Several other equities analysts have also recently weighed in on the company. UBS Group set a €46.00 ($53.49) price objective on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Thursday, May 9th. DZ Bank reissued a “buy” rating on shares of Fresenius SE & Co KGaA in a research report on Wednesday, May 8th. Deutsche Bank set a €65.00 ($75.58) price objective on Fresenius SE & Co KGaA and gave the stock a “buy” rating in a research report on Tuesday, May 7th. Credit Suisse Group set a €50.00 ($58.14) price objective on Fresenius SE & Co KGaA and gave the stock a “neutral” rating in a research report on Monday, May 6th. Finally, Independent Research set a €53.00 ($61.63) price target on Fresenius SE & Co KGaA and gave the company a “neutral” rating in a report on Friday, May 3rd. Ten equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Fresenius SE & Co KGaA has a consensus rating of “Buy” and a consensus price target of €59.55 ($69.24).
FRA FRE opened at €47.27 ($54.97) on Wednesday. Fresenius SE & Co KGaA has a twelve month low of €60.16 ($69.95) and a twelve month high of €80.00 ($93.02).
Fresenius SE & Co KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care worldwide. The company operates through Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed segments. The Fresenius Medical Care segment offers products for patients with chronic kidney failure.
See Also: Why are gap-down stocks important?
Receive News & Ratings for Fresenius SE & Co KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius SE & Co KGaA and related companies with MarketBeat.com's FREE daily email newsletter.